Close

Pfizer buys Swiss preclinical stage firm Redvax

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Pfizer has purchased a controlling stake in Redvax, a spin-off from Swiss biopharmaceutical firm Redbiotec.

Terms of the transaction were not disclosed.

Redvax is a preclinical stage company, which develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of cytomegalovirus (CMV) and a further undisclosed field.

Pfizer senior vice-president of vaccine research and early development Kathrin Jansen said: “Through the acquisition of the Redvax innovative CMV vaccine platform and expertise, we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”

The deal allows Pfizer to gain access to a preclinical human CMV vaccine candidate, in addition to intellectual property and a technology platform related to a second, undisclosed vaccine programme.

The CMV vaccine programme is said to be in line with Pfizer’s portfolio of investigational vaccines, while CMV is a herpes virus, infecting 50%-90% of the adult population, with a majority remaining asymptomatic.

Redbiotec CEO and Redvax managing director Christian Schaub said: “We are pleased to have completed this deal with Pfizer, a global leader in vaccines.

“This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families.”

According to US Centres for Disease Control and Prevention (CDC), 5,000 children each year develop health problems caused by CMV such as hearing or vision loss and mental disability.

 

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back